George Weiner, MD, director of University of Iowa (UI) Holden Comprehensive Cancer Center, will step down from the leadership role on March 31. Dr. Weiner is a past president of AACI. Michael Henry, PhD, deputy director and professor in the UI Department of Molecular Physiology and Biophysics, will serve as interim director of the cancer center, effective April 1.
Registration is open for the 15th Annual AACI Clinical Research Innovation (CRI) Meeting, which will be held June 26-28 at the Loews Chicago O'Hare Hotel in Rosemont, IL. This year’s meeting theme, "Taking Innovations in Clinical Research From Abstract to Reality," aims to stimulate cancer center interactions and maximize resources by creating opportunities for peer-to-peer networking and collaboration.
Registration is now open for AACI's joint Hill Day with the American Association for Cancer Research (AACR), which will take place in person in Washington, DC, on Thursday, May 18. AACI is also accepting recommendations for Cancer Research Ally Award nominees and Hill Day speakers.
Seven new members have been selected to join AACI’s Physician Clinical Leadership Initiative (PCLI) Steering Committee. The new members’ terms began February 1. PCLI pursues a variety of objectives, including developing better methods to disseminate information across cancer centers, identifying and addressing oncology care model barriers, faculty career development, and measuring quality.
AACI welcomes the Prevent Cancer Foundation® to its sustaining members. The Prevent Cancer Foundation is the only U.S.-based nonprofit organization solely dedicated to cancer prevention and early detection. Founded in 1985, the foundation focuses its work in four areas: research, education, outreach, and advocacy.
The AACI Physician Clinical Leadership Initiative (PCLI) distributed surveys to understand unintended consequences of the 21st Century Cures Act mandate on the immediate release of clinical information. JCO Oncology Practice has published a report based on the survey’s findings, "Impact of the Immediate Release of Clinical Information Rules on Health Care Delivery to Patients With Cancer." AACI PCLI steering committee member Taher Abu Hejleh, MBBS, is the lead author.
In 2022, AACI focused on leadership, hosting the inaugural Leadership Diversity and Development Initiative (LDDI) Workshop and its first-ever meeting designed for new cancer center directors. Also in 2022, the association welcomed Ellis Fischel Cancer Center, Houston Methodist Dr. Mary and Ron Neal Cancer Center, Koch Institute for Integrative Cancer Research at MIT, and Northwell Health Cancer Institute.
AACI cancer center directors are invited to submit nominations for the 2023 Champion for Cures Award by Friday, March 31. The award will be presented during the 2023 AACI/CCAF Annual Meeting, October 1-3, at the Salamander Washington DC.
Vitalief is a Functional Service Provider (FSP) offering robust solutions to research and clinical trial organizations that are founded in a future-ready, flexible, people-first culture to deliver greater value for client organizations and our employees.
Visit us at the 15th Annual AACI CRI Meeting! Stop by our exhibit booth to learn how we are addressing the healthcare human capital epidemic with innovative resource, advisory, and managed services.
As a young researcher fresh out of graduate school, MUSC Hollings Cancer Center’s Benjamin Toll, PhD, was thrilled to present his research at the annual conference of the Society for Research on Nicotine & Tobacco (SRNT) in 2002. Fast forward 21 years and he’s now taking the helm. Dr. Toll was recently elected president-elect of SRNT and will serve a three-year term.
Duke Cancer Institute surgical oncologist Betty Tong, MD, MHS, MSME, BME, has won the inaugural "Extraordinary Women in Cardiothoracic Surgery Award" established by the Society of Thoracic Surgeons and Women in Thoracic Surgery.
Huntsman Cancer Institute's Alana Welm, PhD, received a five-year extension in her role as Ralph E. and Willia T. Main Presidential Endowed Chair in Cancer Research; Aik Choon Tan, PhD, was named the Jon and Karen Huntsman Presidential Professor in Cancer Research; and Brad Cairns, PhD, was named the inaugural Jon M. Huntsman Presidential Endowed Chair in Cancer Research.
Five University of Michigan Rogel Cancer Center members were elected as 2022 fellows of the American Association for the Advancement of Science. The Rogel fellows are: Thomas Carey, PhD; Joerg Lahann, PhD; Marina Pasca di Magliano, PhD; Donna Martin, MD, PhD; and Duxin Sun, PhD.
Fox Chase Cancer Center has achieved Magnet designation for nursing excellence from the American Nurses Credentialing Center for the sixth consecutive time. Fox Chase has held Magnet status continuously since 2000, when it became the first hospital in Pennsylvania and the first specialty hospital in the United States to achieve Magnet designation.
Director of the Duke Cancer Institute Office of Cancer Research Training & Education Coordination, Gerard C. Blobe, MD, PhD, has been elected as a 2022 AAAS Fellow by the American Association for the Advancement of Science.
President Joe Biden has appointed Ohio State University’s Fred Tabung, PhD, MSPH, to the National Cancer Advisory Board. He is one of six individuals from across the United States tapped to serve in this important role to help guide the national cancer research program agenda.
Kevan Shokat, PhD, has received the Sjöberg Prize from the Swedish Academy of Sciences, the same body that awards the Nobel prizes for physics, chemistry and economics. He was also recently recognized by the National Academy of Sciences with the organization’s annual Award for Scientific Discovery.
Jennifer Trowbridge, PhD, has received an Emerging Leader Award from The Mark Foundation for Cancer Research. The foundation presented six of these awards, totaling $4.5 million, to outstanding early-career investigators for projects aimed at addressing unmet needs in cancer research.
The National Comprehensive Cancer Network (NCCN) has announced that Terrance Mayes, EdD, associate director for diversity, equity & inclusion at the Stanford Cancer Institute, will serve as the inaugural chair of the NCCN Diversity, Equity & Inclusion Directors Forum.
City of Hope Comprehensive Cancer Center has received the highest ranking possible—"exceptional"—by the National Cancer Institute (NCI), and was awarded more than $23 million in competitive funding through renewal of its NCI Cancer Center Support Grant to support research, cancer training and education, and community outreach over the next five years. Steven T. Rosen, MD, is the cancer center's director.
The University of Texas MD Anderson Cancer Center has been awarded 15 grants totaling $19.38 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of cancer research projects across the institution.
The University of Pittsburgh was awarded a five-year, $11.2 million grant from the National Institutes of Health (NIH) to support a Head and Neck Cancer Specialized Program of Research Excellence (SPORE). The award will be led by Robert L. Ferris, MD, PhD, director of UPMC Hillman Cancer Center, and Heath Skinner, MD, PhD, chair and associate professor, Department of Radiation Oncology.
Baylor College of Medicine has been awarded more than $5.8 million in grants by the Cancer Prevention & Research Institute of Texas (CPRIT) to support innovative translational research and cancer treatments. CPRIT awarded more than $90 million in grants to institutions across Texas to advance the fight against cancer, including four grants to Baylor.
Tess Thompson, PhD, MPH, has received a five-year $1.1 million grant from the National Cancer Institute to study unmet social needs of cancer patients and their caregivers, with the ultimate aim of improving outcomes for both members of a pair.
Jose Javier Bravo-Cordero, PhD, received an Emerging Leader Award from The Mark Foundation for his project, Impact of Dormant Cancer Cells on the Brain Microenvironment. Dr. Bravo-Cordero will use high-resolution imaging technology to understand how dormant cancer cells instruct neuronal tissue at the single cell level.
Jennifer Hatcher, PhD, MPH, MSN, has been appointed associate director of Inclusivity, Diversity, Equity and Accessibility for the University of Arizona Cancer Center. The appointment initiates establishment of a new office of diversity, equity, and inclusion at the center. Dr. Hatcher currently oversees community outreach and engagement and will serve as interim in that capacity while a national search is conducted.
Jordan Berlin, MD, Ingram Professor of Cancer Research, has been named director of Vanderbilt’s Division of Hematology and Oncology. The appointment was effective January 1, but Dr. Berlin had served as interim director for six months prior to that date.
Yaguang Xi, MD, PhD, MBA, has been appointed associate director for translational sciences at the LSU-LCMC Cancer Center. Dr. Xi is a professor and vice chair for research in the Department of Genetics at LSU Health Sciences Center. His research interests include cancer therapeutics, cancer chemoprevention, health disparities, metastasis, immunotherapy, and new drug development.
Priyamvada Rai, PhD, is the new Tumor Biology Research Program co-leader at Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System. In her role, Dr. Rai will boost interactions and collaborations among Sylvester’s researchers to better understand how cancer cells behave.
The Cancer Research Institute has announced that two members of its scientific advisory council (SAC), Nina Bhardwaj, MD, PhD, of The Tisch Cancer Institute at Mount Sinai, and Elizabeth M. Jaffee, MD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, have been appointed SAC associate directors.
Jaime Merchán, MD, is the new Translational and Clinical Oncology Research Program co-leader at Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System. Dr. Merchán, who also directs Sylvester’s Phase 1 Clinical Trials Program, is leading the program alongside C. Ola Landgren, MD, PhD, director of the cancer center’s new Myeloma Research Institute.
Huntsman Cancer Foundation Chair and CEO Peter Huntsman has announced that Kim Wirthlin will be president and chief operating officer. During her 16 years of employment at the University of Utah, Wirthlin has worked as the vice president of government relations and as the chief marketing and communications officer for the university’s health care system and Health Sciences.
New data from a Yale Cancer Center-led clinical trial shows improved rates of survival and reduced risk of recurrence in patients taking osimertinib, a targeted therapy for non-small cell lung cancer (NSCLC). The phase III ADAURA clinical trial assessed the safety and efficacy of osimertinib in patients with surgically removed (completely resected) stage IB-IIA NSCLC, who were previously treated with or without adjuvant chemotherapy.
Cedars-Sinai Cancer investigators have developed a new nanotechnology-based test that can detect and profile prostate cancers – even in microscopic amounts. Their work suggests that this "liquid biopsy" test could spare many patients unnecessary treatment-related side effects, directing them instead to effective therapies that could prolong their lives.
Women who ovulate for longer over their lifetimes have a higher risk of developing ovarian cancer, suggesting that suppressing ovulation can lower this risk. A new international study offers new clues as to how oral contraceptives, pregnancy, and breastfeeding impact ovarian cancer risk beyond simply suppressing ovulation and how this link may vary among different ovarian cancer subtypes.
The UNM Comprehensive Cancer Center will soon be examining the potential for using cutting-edge radioisotope technology called 177 Lu-PSMA-617 to treat advanced prostate cancer. The center will be one of a few sites in the country participating in a clinical trial to expand the application of theranostic treatment to patients with prostate cancer. This type of treatment is currently used at the cancer center for neuroendocrine tumors.
University of Florida researchers have made a significant discovery in the development highly targeted chemotherapies for breast and other cancers. The scientists have spent years developing antibody-drug conjugates, or ADCs, that combine a protective protein and a cancer-killing drug. Recently published findings detail the first time a particular type of cancer-killing "payload" has been used for ADC development.
Risk model-based lung cancer screening strategies, which select individuals based on personal risk, are more cost effective than current recommendations based solely on age and smoking history, according to a study led by the Cancer Intervention and Surveillance Modeling Network Lung Working Group, which includes researchers from The University of Texas MD Anderson Cancer Center.
The severity of immune-mediated intestinal diseases such as graft-versus-host disease or inflammatory bowel diseases is known to be associated with alterations in the gut microbiome, but what leads to such disruption has remained a mystery. Researchers at Baylor College of Medicine and collaborating institutions report that alterations in the gut microbiome are connected to an increase in the oxygen levels in the intestine that follows immune-mediated intestinal damage.
It is now widely understood that cancer is a disease of acquired defects in genes and gene function. A recently published article addresses new quantitative approaches to better define and measure these defects in gene function, known as epigenetics, and their interplay with the genetic landscape of cancer.
A new clinical and preclinical study from UCLA Jonsson Comprehensive Cancer Center identifies the DNA roots of resistance to targeted cancer therapy, providing a possible strategy to address a vexing issue in cancer therapeutics. To understand how the cancer genome changes immediately after the initiation of targeted therapy—potentially generating new genetic variants capable of escaping the therapy—the researchers focused on metastatic cutaneous melanoma.
Investigators from Rutgers Cancer Institute of New Jersey, together with RWJBarnabas Health, found that a higher risk of mortality in Black breast cancer survivors is associated with a history of cigarette smoking along with regular alcohol consumption at the time of diagnosis.
Investigators from Roswell Park Comprehensive Cancer Center were among the experts whose work was highlighted at the 2023 Tandem Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and Center for International Blood and Marrow Transplant Research.
A research team at Vanderbilt University Medical Center has detailed a stepwise method for analyzing large data sets (more than 550,000 individuals) that can improve dramatically the accuracy of "clonal hematopoiesis of indeterminate potential,” or CHIP, determination.
The protein STAT5 has long been an appealing target against cancer, but after decades of research it was consigned to the "undruggable" category. Now, University of Michigan Rogel Cancer Center researchers have found success with a new approach.
Researchers at Washington University School of Medicine in St. Louis have discovered that the difference between people who do and do not respond to immunotherapy may have to do with an immune cell known as CD5+ dendritic cells because they bear the protein CD5 on their outer surfaces.
A type of cell that plays a key role in pancreatic cancer can trace its origin back to a structure that forms during embryonic development, new research at MUSC Hollings Cancer Center shows. This new data is the first to show the cellular origin of normal pancreatic fibroblasts and cancer-associated fibroblasts that influence tumor progression.
A study led by UF Health Cancer Center researchers found that Black and Hispanic adults had less knowledge and were less likely to undergo cancer genetic testing than white adults. The researchers compared self-reported cancer genetic testing knowledge and use by race and ethnicity. They also looked at the perceived importance of genetic information for cancer care in relation to the uptake of cancer genetic testing.
Age-based heuristics, or "rules of thumb," can lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new analysis of more than 500,000 patient records.
Fox Chase Cancer Center has formed a new Department of Urology that will be chaired by Alexander Kutikov, MD, FACS. On average, the department publishes and contributes to over 100 peer-reviewed publications, book chapters, and abstracts every year. Fox Chase urology is also a nationally recognized hub for the surgical training of residents and Society of Urologic Oncology and Genitourinary Reconstruction Fellows.
Pending approval by The Ohio State University Board of Trustees, a new interdisciplinary research facility in the university’s Carmenton innovation district will be named Pelotonia Research Center. The naming is in recognition of Pelotonia’s philanthropic support for cancer research at OSUCCC–James.
Registration is open for the 15th Annual AACI CRI Meeting, June 26-28, 2023, at Loews Chicago O'Hare Hotel in Rosemont, IL.
For those who are unable to attend the CRI meeting in person, a virtual option is available. To register as a virtual attendee, select the "Member - Virtual Only" registration type. This will give you access to all sessions held in the main ballroom and a virtual breakout session. Virtual registration rates will remain the same. Login information will be provided closer to the meeting.
Registration is now open for the 2023 AACI/CCAF Annual Meeting, October 1-3, 2023, at the Salamander Washington DC.
For those who are unable to attend the annual meeting in person, a virtual option is available. To register as a virtual attendee, select the "Member - Virtual Only" registration type. This will give you access to all sessions held in the main ballroom and a virtual breakout session. Virtual registration rates will remain the same. Login information will be provided closer to the meeting.
Save the date for the 2024 AACI/CCAF Annual Meeting, October 20-22, 2024, at Loews Chicago Hotel in Chicago, IL.